|
|
||||||||
AJP - Endocrinology and Metabolism, Vol 256, Issue 2 E322-E330, Copyright © 1989 by American Physiological Society
ARTICLES |
P. M. Radosevich, D. B. Lacy, L. L. Brown, P. E. Williams and N. N. Abumrad
Department of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.
The effects of centrally administered beta-endorphins on glucose homeostasis in the conscious dog were studied. Intracerebroventricular administration of beta-endorphin (0.2 mg/h) caused a 70% increase in plasma glucose. The mechanism of the hyperglycemia was twofold: there was an early increase in glucose production and a late inhibition of glucose clearance. These changes are explained by marked increases in plasma epinephrine (30-fold) and norepinephrine (6-fold) that occurred during infusion of beta-endorphin. Central administration of beta-endorphin also resulted in increased levels of adrenocorticotropic hormone and cortisol. In addition there was an increase in plasma insulin but no increase in plasma glucagon. Intravenous administration of beta-endorphin did not alter glucose homeostasis. Intracerebroventricular administration of acetylated beta-endorphin did not perturb glucose kinetics or any of the hormones that changed during infusion of the unacetylated peptide. We conclude that beta-endorphin acts centrally to cause hyperglycemia by stimulating sympathetic outflow and the pituitary-adrenal axis. Acetylation of beta-endorphin abolishes the in vivo activity of the peptide.
This article has been cited by other articles:
![]() |
B. E. Levin, C. Magnan, S. Migrenne, S. C. Chua Jr., and A. A. Dunn-Meynell F-DIO obesity-prone rat is insulin resistant before obesity onset Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R704 - R711. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |